Phase I dose-escalation study to evaluate safety and clinical activity of c-MET inhibitor ABN401 in patients with advanced solid tumor

D. H. Lee, A. Roohullah, B. C. Cho, C. Lemech, P. de Souza, M. Millward, J. Choi, K. E. Park, M. Lee, Y. Kim, S. Park, J. Lee, J. Kim, Y. K. Shin, J-Y. Han

Research output: Contribution to journalAbstract/Meeting Abstractpeer-review

Original languageEnglish
Pages (from-to)S1029-S1030
Number of pages2
JournalAnnals of Oncology
Publication statusPublished - 2021
EventCongress of the European-Society-for-Medical-Oncology (ESMO) -
Duration: 16 Sept 202121 Sept 2021

Cite this